ArticlePloS one2026
Integrated computational analysis identifies FABP4, PTGS2, and HPGD as Key molecular targets linking PET microplastic exposure to metabolic dysfunction-associated steatotic liver disease.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) affects 25-38% of the global population, yet the contribution of environmental polyethylene terephthalate (PET) microplastics to its pathogenesis remains unclear. PET microplastics accumulate in the liver at approximately 4.6 particles per gram of tissue and have been implicated in metabolic disturbance, oxidative stress, and inflammation, but their molecular targets and mechanisms in MASLD are not well defined.
methodsWe integrated three GEO microarray cohorts (GSE37031, GSE63067, GSE89632) and performed differential expression analysis, weighted gene co-expression network analysis (WGCNA), and PET target prediction using ChEMBL, PharmMapper, and SwissTargetPrediction. Functional enrichment, protein-protein interaction network analysis, CIBERSORT-based immune deconvolution, molecular docking, and 100 ns molecular dynamics simulations were employed to identify and validate hub genes.
resultsIntegration of MASLD transcriptomes and PET target predictions yielded 19 overlapping genes enriched in pathways related to lipid metabolism, fatty acid degradation, glycolysis/gluconeogenesis, and chemical carcinogenesis. Network topology consistently highlighted FABP4, PTGS2, and HPGD as central hub genes. Immune deconvolution revealed MASLD-associated alterations characterized by increased M2 macrophages and γδ T cells, with decreased monocytes, dendritic cells, and naive B cells. PTGS2 and FABP4 expression showed strong correlations with innate immune cells. Molecular docking demonstrated favorable PET binding to all three proteins (-6.3 to -6.9 kcal/mol), and molecular dynamics simulations confirmed stable complexes over 100 ns, with predominantly hydrophobic interactions.
conclusionsThrough integrated bioinformatics analysis and molecular simulation, this study identifies FABP4, PTGS2, and HPGD as potential molecular targets through which PET microplastics may influence lipid metabolism, prostaglandin signaling, and innate immune responses in MASLD. Molecular docking and dynamics simulations suggest favorable binding interactions between PET and these proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.